ArticleHuman vaccines & immunotherapeutics2017
A bioluminescent imaging mouse model for Marburg virus based on a pseudovirus system.
Article in Human vaccines & immunotherapeutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 42 citations in OpenAlex.
- A surrogate BSL2-compliant infection model recapitulating key aspects of human Marburg virus disease.Emerging microbes & infections · 2025Article
- Development and characterization of a pseudovirus system for human Aichi virus: in vitro and in vivo analysis.Virology journal · 2025Article
- A Bioluminescent Imaging Mouse Model for Seasonal Influenza Virus Infection Based on a Pseudovirus System.Viruses · 2025Article
- Development of a neutralization assay and bioluminescent imaging mouse model for Dehong virus (DEHV) using a pseudovirus system.Microbiology spectrum · 2025Article
- An Mpox Multi-Antigen-Tandem Bivalent mRNA Candidate Vaccine Effectively Protects Mice Against the Vaccinia Virus.Vaccines · 2025Article
- [Development of a new platform for testing antiviral drugs using coronavirus-infected human nasal mucosa organoids].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2024Article
- Safety and neutralization antibody levels of inactivated SARS-CoV-2 vaccine in adult patients with Myasthenia Gravis: a prospective observational cohort study.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024Observational
- Natural products as a source of Coronavirus entry inhibitors.Frontiers in cellular and infection microbiology · 2024Review
- Monkeypox virus quadrivalent mRNA vaccine induces immune response and protects against vaccinia virus.Signal transduction and targeted therapy · 2023Article
- Pseudotyped Viruses for Marburgvirus and Ebolavirus.Advances in experimental medicine and biology · 2023Article
- Production and characterization of lentivirus vector-based SARS-CoV-2 pseudoviruses with dual reporters: Evaluation of anti-SARS-CoV-2 viral effect of Korean Red Ginseng.Journal of ginseng research · 2023Article
- Assays Based on Pseudotyped Viruses.Advances in experimental medicine and biology · 2023Article
- Pseudotyped Viruses.Advances in experimental medicine and biology · 2023Article
- Screening and identification of HTNVVirologica Sinica · 2022Article
- Overview of Neutralization Assays and International Standard for Detecting SARS-CoV-2 Neutralizing Antibody.Viruses · 2022Review
- Developing Pseudovirus-Based Neutralization Assay against Omicron-Included SARS-CoV-2 Variants.Viruses · 2022Article
- Pseudovirus-Based Assays for the Measurement of Antibody-Mediated Neutralization of SARS-CoV-2.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Discovery and evolution of 12N-substituted aloperine derivatives as anti-SARS-CoV-2 agents through targeting late entry stage.Bioorganic chemistry · 2021Article
- An optimized and robust SARS-CoV-2 pseudovirus system for viral entry research.Journal of virological methods · 2021Article
- SARS-CoV-2 Spike Pseudoviruses: A Useful Tool to Study Virus Entry and Address Emerging Neutralization Escape Phenotypes.Microorganisms · 2021Article
Corrections and comments
- Commented on by
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Marburg virus (MARV) can cause lethal hemorrhagic fever in humans. Handling of MARV is restricted to high-containment biosafety level 4 (BSL-4) facilities, which greatly impedes research into this virus. In this study, a high titer of MARV pseudovirus was generated through optimization of the HIV backbone vectors, the ratio of backbone vector to MARV glycoprotein expression vector, and the transfection reagents. An in vitro neutralization assay and an in vivo bioluminescent imaging mouse model for MARV were developed based on the pseudovirus. Protective serum against MARV was successfully induced in guinea pigs, which showed high neutralization activity in vitro and could also protect Balb/c mice from MARV pseudovirus infection in vivo. This system could be a convenient tool to enable the evaluation of vaccines and therapeutic drugs against MARV in non-BSL-4 laboratories.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.